Drugs / Berubicin
Berubicin
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05082493 | Dec 2023 | malignant glioma | WPD Pharmaceuticals Sp. z o.o. | Withdrawn | No outcome recorded |
| Phase 1 | NCT00527410 | Oct 2006 → Dec 2008 | neoplastic meningitis | Biogen | Terminated | No outcome recorded |
| Phase 1 | NCT00512460 | Sep 2006 → Mar 2010 | brain neoplasm, leukemia, lymphoma, neoplastic meningitis | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00526812 | Nov 2005 → Dec 2008 | glioma | Biogen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04915404 | Dec 2022 → Dec 2023 | glioblastoma | WPD Pharmaceuticals Sp. z o.o. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04762069 | May 2021 → Apr 2026 overdue | adult glioblastoma | CNS Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00538343 | Oct 2007 → Dec 2008 | metastatic malignant neoplasm in the brain | Biogen | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Berubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05082493 ↗ |
| Known as | Berubicin HCl | “Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once...” NCT04915404 ↗1“Berubicin HCL - MTD phase” NCT05082493 ↗ |
| Known as | Berubicin Hydrochloride | “berubicin hydrochloride (RTA 744)” NCT00538343 ↗ |
| Known as | Berubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110580 ↗ |
| Known as | Berubicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110580 ↗ |
| Known as | RTA 744 | “berubicin hydrochloride (RTA 744)” NCT00538343 ↗ |
| Known as | WP-744 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110580 ↗ |
| Action | Inhibit | “a cytotoxic anthracycline topoisomerase II inhibitor” NCT04762069 ↗ |
| Modality | Small molecule | “RTA 744 is a close chemical analogue of the well characterized anti-cancer agent doxorubicin.” NCT00526812 ↗ |
| Route | Intravenous | “you will receive RTA 744 through a needle in your vein over a 2-hour period” NCT00512460 ↗ |